Skip to main content
SpringerLink
Log in

Telmisartan: clinical evidence across the cardiovascular and renal disease continuum

  • Review Article
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The cardiovascular and renal disease continuum is a well-established concept describing the emergence and subsequent progressive nature of cardiovascular and renal disease. Several trials have demonstrated the benefits of angiotensin receptor blockers at different stages of the continuum. This review focuses on clinical evidence of telmisartan, generated to date, across all four stages of the cardiovascular and renal disease continuum (i.e. risk factors, subclinical organ damage, overtly manifested disease and end-stage disease).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. WHO|cardiovascular diseases (CVDs) [Internet]. WHO. [cited 2015 Oct 6]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/.

  2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244–63.

    Article  CAS  PubMed  Google Scholar 

  3. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850–70.

    Article  PubMed  Google Scholar 

  4. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev. 2000;18(2):127–54.

    Article  CAS  Google Scholar 

  5. Boehringer Ingelheim International GmbH. Micardis summary of product characteristics. European public assessment report [online]. [Internet]. [cited 2016 Feb 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000209/WC500027641.pdf.

  6. Neutel J, Smith D. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther. 1998;15:206–17.

    CAS  Google Scholar 

  7. Stangier J, Schmid J, Türck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12 pt 1):1312–22.

    CAS  PubMed  Google Scholar 

  8. Stangier J, Su CA, Hendriks MG, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1373–9.

    CAS  PubMed  Google Scholar 

  9. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28(4):149–67.

    Article  CAS  PubMed  Google Scholar 

  10. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002;302(3):1089–95.

    Article  CAS  PubMed  Google Scholar 

  11. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41–6.

    CAS  PubMed  Google Scholar 

  12. Stangier J, Su CA, van Heiningen PN, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38(5):672–85.

    Article  CAS  PubMed  Google Scholar 

  13. Redon J, Luque-Otero M, Martell N, et al. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 2005;5(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  14. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993–1002.

    Article  CAS  PubMed  Google Scholar 

  15. Fujimoto M, Masuzaki H, Tanaka T, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004;576(3):492–7.

    Article  CAS  PubMed  Google Scholar 

  16. Inoue T, Taguchi I, Abe S, et al. Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. J Clin Pharm Ther. 2011;36(1):103–10.

    Article  CAS  PubMed  Google Scholar 

  17. Cicha I, Urschel K, Daniel WG, et al. Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-α. Clin Hemorheol Microcirc. 2011;48(1):65–73.

    PubMed  Google Scholar 

  18. Scalera F, Martens-Lobenhoffer J, Bukowska A, et al. Effect of telmisartan on nitric oxide–asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension. 2008;51(3):696–703.

    Article  CAS  PubMed  Google Scholar 

  19. Yamagishi S, Matsui T, Nakamura K, et al. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept Lett. 2008;15(8):850–3.

    Article  CAS  PubMed  Google Scholar 

  20. Kusunoki H, Taniyama Y, Azuma J, et al. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension. 2012;59(2):308–16.

    Article  CAS  PubMed  Google Scholar 

  21. Siragusa M, Sessa WC. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler Thromb Vasc Biol. 2013;33(8):1852–60.

    Article  CAS  PubMed  Google Scholar 

  22. Myojo M, Nagata D, Fujita D, et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. PLoS One. 2014;9(5):e96948.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Xu S, Song H, Huang M, et al. Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of the peroxisome proliferator-activated receptor-δ pathway. Int J Mol Med. 2014;34(3):828–34.

    CAS  PubMed  Google Scholar 

  24. Mikami D, Kimura H, Kamiyama K, et al. Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells. Hypertens Res. 2014;37(5):422–31.

    Article  CAS  PubMed  Google Scholar 

  25. Sugimoto K, Qi NR, Kazdová L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47(5):1003–9.

    Article  CAS  PubMed  Google Scholar 

  26. Williams B, Lacourcière Y, Schumacher H, et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23(9):610–9.

    Article  CAS  PubMed  Google Scholar 

  27. Gosse P, Schumacher H. Effect of telmisartan vs. ramipril on “dipping” status and blood pressure variability: pooled analysis of the PRISMA studies. Hypertens Res. 2014;37(2):151–7.

    Article  CAS  PubMed  Google Scholar 

  28. Zou Z, Xi G-L, Yuan H-B, et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2009;23(5):339–49.

    Article  CAS  PubMed  Google Scholar 

  29. Takagi H, Mizuno Y, Goto S-N, et al. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: a meta-analysis of head-to-head randomized trials. Int J Cardiol. 2013;167(6):3051–6.

    Article  PubMed  Google Scholar 

  30. Takagi H, Niwa M, Mizuno Y, et al. A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. Hypertens Res. 2013;36(11):959–66.

    Article  CAS  PubMed  Google Scholar 

  31. Takagi H, Niwa M, Mizuno Y, et al. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction. Hypertens Res. 2013;36(7):627–33.

    Article  CAS  PubMed  Google Scholar 

  32. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res. 2008;31(1):7–13.

    Article  CAS  PubMed  Google Scholar 

  33. Takagi H, Umemoto T, All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens. 2014;8(8):578–92.

    Article  CAS  PubMed  Google Scholar 

  34. Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. Int J Cardiol. 2012;156(1):92–6.

    Article  PubMed  Google Scholar 

  35. Takagi H, Umemoto T. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials. Int J Cardiol. 2012;155(3):448–51.

    Article  PubMed  Google Scholar 

  36. Hamamoto Y, Honjo S, Kawasaki Y, et al. Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study. Clin Drug Investig. 2012;32(9):577–82.

    Article  CAS  PubMed  Google Scholar 

  37. Takagi H, Niwa M, Mizuno Y, et al. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229–35.

    Article  CAS  PubMed  Google Scholar 

  38. Takagi H, Umemoto T. Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol. 2012;157(3):403–7.

    Article  PubMed  Google Scholar 

  39. Inoue T, Morooka T, Moroe K, et al. Effect of telmisartan on cholesterol levels in patients with hypertension—Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007;39(5):372–6.

    Article  CAS  PubMed  Google Scholar 

  40. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27(7):457–64.

    Article  CAS  PubMed  Google Scholar 

  41. Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res. 2008;31(5):921–9.

    Article  CAS  PubMed  Google Scholar 

  42. Huang G-Z, Tang Y-H, Wang B-Y, et al. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J. 2011;32(10):1017–21.

    PubMed  Google Scholar 

  43. Murakami K, Wada J, Ogawa D, et al. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal Fat Depot Intervention Program of Okayama (ADIPO). Diab Vasc Dis Res. 2013;10(1):93–6.

    Article  PubMed  Google Scholar 

  44. Mori Y, Tanaka T, Matsuura K, et al. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther. 2011;28(8):698–706.

    Article  CAS  PubMed  Google Scholar 

  45. Chetty VT, Damjanovic S, Gerstein H, et al. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press. 2014;23(1):54–60.

    Article  CAS  PubMed  Google Scholar 

  46. Choi GJ, Kim HM, Kang H, et al. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016;32(7):1303–9.

    Article  CAS  PubMed  Google Scholar 

  47. Takagi H, Mizuno Y, Yamamoto H, et al. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res. 2013;36(4):368–73.

    Article  CAS  PubMed  Google Scholar 

  48. Takagi H, Yamamoto H, Iwata K, et al. Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;156(2):238–41.

    Article  PubMed  Google Scholar 

  49. Klinghammer L, Urschel K, Cicha I, et al. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis—influence on IP-10, TNF-α and MCP-1. Cytokine. 2013;62(2):290–6.

    Article  CAS  PubMed  Google Scholar 

  50. Hasegawa H, Takano H, Narumi H, et al. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertens Res. 2011;34(11):1179–84.

    Article  CAS  PubMed  Google Scholar 

  51. Yamaguchi K, Wakatsuki T, Soeki T, et al. Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients. Circ J. 2014;78(1):240–7.

    Article  CAS  PubMed  Google Scholar 

  52. Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55(10):976–82.

    Article  CAS  PubMed  Google Scholar 

  53. Takagi H, Umemoto T. A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation. Hypertens Res. 2014;37(9):845–51.

    Article  CAS  PubMed  Google Scholar 

  54. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30(6):1351–6.

    Article  CAS  PubMed  Google Scholar 

  55. Dogotar O, Sopetik V, Kotovskaya Y. 7D.12: telmisartan monotherapy effects on microcirculation in patients with uncomplicated arterial hypertension. J Hypertens. 2015;33(Suppl 1):e103.

    Article  PubMed  Google Scholar 

  56. Pelliccia F, Pasceri V, Cianfrocca C, et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis. 2010;210(2):510–5.

    Article  CAS  PubMed  Google Scholar 

  57. Takagi H, Mizuno Y, Iwata K, et al. Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials. Int J Cardiol. 2013;165(3):564–7.

    Article  PubMed  Google Scholar 

  58. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Circulation. 2009;120(14):1380–9.

    Article  CAS  PubMed  Google Scholar 

  59. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  PubMed  Google Scholar 

  60. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–8.

    Article  CAS  PubMed  Google Scholar 

  61. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–17.

    Article  CAS  PubMed  Google Scholar 

  62. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–61.

    Article  CAS  PubMed  Google Scholar 

  63. Takagi H, Yamamoto H, Iwata K, et al. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013;167(4):1443–9.

    Article  PubMed  Google Scholar 

  64. Ogawa H, Soejima H, Matsui K, et al. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): biomarker study. Eur J Prev Cardiol. 2016;23(9):913–21.

    Article  PubMed  Google Scholar 

  65. Pan G, Zhou X, Zhao J. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis. Cardiovasc Ther. 2014;32(4):184–8.

    Article  CAS  PubMed  Google Scholar 

  66. Morris DR, Cunningham MA, Ahimastos AA, et al. TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomized controlled trial. Trials. 2015;16:274.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.

    Article  CAS  PubMed  Google Scholar 

  68. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83.

    Article  Google Scholar 

  69. Foulquier S, Böhm M, Schmieder R, et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular disease subanalysis. J Hypertens. 2014;32(6):1334–41.

    Article  CAS  PubMed  Google Scholar 

  70. Yokota T, Osanai T, Hanada K, et al. Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessels. 2010;25(6):460–8.

    Article  PubMed  Google Scholar 

  71. Yusuf S, Diener H-C, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Diener H-C. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl. 2009;27(5):S31–6.

    Article  CAS  PubMed  Google Scholar 

  73. Zankl AR, Ivandic B, Andrassy M, et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol. 2010;99(12):787–94.

    Article  CAS  PubMed  Google Scholar 

  74. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  CAS  PubMed  Google Scholar 

  75. Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364–9.

    Article  CAS  PubMed  Google Scholar 

  76. Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transpl. 2008;23(10):3174–83.

    Article  CAS  Google Scholar 

  77. Tokunaga M, Kabashima N, Serino R, et al. Renoprotective effects of telmisartan in patients with advanced chronic kidney disease. Clin Nephrol. 2010;73(2):139–46.

    Article  CAS  PubMed  Google Scholar 

  78. Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol. 2001;77(2–3):131–138–140.

  79. Sakata Y, Shiba N, Takahashi J, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015;36(15):915–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Services, Intas Pharmaceuticals Ltd., 2nd floor, Chinubhai Centre, Ashram Road, Ahmedabad, Gujarat, 380009, India

    Piyush Patel

Authors
  1. Piyush Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piyush Patel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, P. Telmisartan: clinical evidence across the cardiovascular and renal disease continuum. Drugs Ther Perspect 33, 77–87 (2017). https://doi.org/10.1007/s40267-016-0366-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0366-6

Keywords

Search

Navigation